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Background: C-reactive protein (CRP) is a nonspecific, acute-phase protein that rises in response to infectious and
non-infectious inflammatory processes. Infections are the single largest cause of neonatal deaths globally.
The primary aim of this study is to examine the association between CRP gene polymorphism and serum levels of
CRP in correlation with early onset sepsis (EOS) infection in newborns living in Taif city, Saudi Arabia. The second
aim is to examine the relationship between specific IgG/IgG subclasses and early onset sepsis (EOS) infection
among these newborns.
Methods: Staphylococcus aureus (S. aureus) is one of the most common organisms related to sepsis infection in the
newborn at King Abdel Aziz Specialist Hospital (KAASH). This study was conducted in Taif city, at KAASH’s neonatal
intensive care unit between March and August 2012. Neonates were consecutively enrolled onto the study having
met our inclusion criteria (as per our research protocol).
The CRP concentration level was analysed using NycoCardW CRP Single Test. CRP -286 (C>T>A) A polymorphisms
were analyzed using Pyrosequencing technology for CRP genotyping. IgG subclasses were analysed in the study
population using ELISA.
Result: Logistic regression analyses showed that the AA and AC genotypes were negatively associated amongst
EOS neonates compared to suspected neonates. The frequency of CC and CT were significantly associated with the
EOS neonates compared to the suspected group. The levels of specific IgG1, IgG2 and IgG3 antibodies were
significantly lower amongst EOS compared to the suspected group.
Conclusions: Taken together, the CRP-286 (C>T>A) A genotype polymorphism and specific IgG antibodies isotype
levels can contribute to a reduced risk of EOS. Furthermore, CRP has a potential use in detecting EOS in neonates,
which may mean earlier detection and management of EOS and subsequently better clinical outcome.
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Sepsis is a systemic response to infection with bacteria,
fungi or protozoa. If not recognised and treated early,
the progression from sepsis to severe sepsis, septic
shock, and multiple organ dysfunction syndrome is inev-
itable [1]. Neonatal early onset sepsis (EOS) is one of the
major causes of morbidity and mortality among newborn
infants occurring in 1% of term and up to 20% of very-* Correspondence: adnamn@gmail.com
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reproduction in any medium, provided the orlow-birth-weight (VLBW) infants [2,3]. The mortality
rate varies from 3% to 50% in early-onset sepsis, and up
to 40% in late-onset sepsis [3]. There is no single defin-
ition of EOS in the newborn; various definitions exist,
each with subtle differences. EOS refers to an infection
of the blood stream proven by culture. EOS is usually
acquired vertically from the mother and manifests in the
first 24 hours to 7 days after birth [4,5], and late onset
disease for infections after 7 days. Scandinavian investi-
gators have used this scheme because infection within
the first 24 hours has a higher mortality rate.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without presenting typical symptoms such as fever. There
is an increased risk of sepsis in neonates, and in particular
preterm infants, due to the incomplete maturity of their
immune system. Reliable methods for detecting and moni-
toring sepsis in the newborns would therefore be benefi-
cial in terms of treatment and management. In older
children and adults, serum/plasma levels of C-reactive
protein (CRP), IgG and IgG subclass have proved useful
indicators of infection and inflammation [6].
CRP is an acute-phase protein produced by the liver as
part of the body’s inflammatory response to bacterial in-
fection and tissue injury. CRP is produced during fetal de-
velopment, preceding the production of IgG [7,8]. The
level of CRP is known to rise in both bacterial and fungal
infections in children beyond the neonatal age, but re-
mains low or undetectable in viral infections [9,10]. CRP
alone can be a good indicator of bacterial infection in pre-
term and term neonates even though it is sensitive in early
infections but not specific [11]. Serum CRP reference
ranges have been identified in neonates, but there is little
information on the levels of CRP in maternal blood com-
pared with those found in cord blood, showing that there
is no appreciable transfer of CRP across the placenta [12].
The influence of genetic variation on the levels of circulat-
ing CRP is estimated to be 40-60% [13], and a functional
polymorphism in the promoter region of the CRP gene
(-286 C>T>A) (rs3091244) has been strongly associated
with the circulating concentrations of CRP [14]. Previous
studies of the functional -286 C>T>A CRP polymorphism
have revealed that the A allele is more common in the Afri-
can American than in the Caucasian population, and this
difference in genotypes is associated with higher CRP levels
in the former population [15]. This suggests that CRP could
have been selected for in the African ancestors, as a benefi-
cial factor for survival from infectious diseases.
IgG antibodies are monomeric, found in all body
fluids, and are the dominating isotype in humoral im-
mune responses, constituting 75% to 80% of all anti-
bodies in the serum. Human IgG is divided into four
subclasses, IgG1- IgG4, where IgG1 is the most common
(66%), followed by IgG2 (24%), IgG3 (7%) and IgG4 (3%)
[16]. IgG1 and IgG3 antibodies are predominantly pro-
duced in response to protein antigens [17], but chronic
stimulation may result in an increased proportion of
IgG4 [18]. In contrast, carbohydrate antigens most often
induce IgG2 responses [17]. The different subclasses dif-
fer in their ability to activate complement, IgG1 and
IgG3 being the most effective ones, IgG2 being a weak
activator, whereas IgG4 does not activate complement.
IgG2 antibodies are very important in targeting encapsu-
lated bacteria. IgG antibodies are the only isotypes that
can cross the placenta in the pregnant woman to help
protect the neonate.CRP increases rapidly during infections and/or inflam-
mation. CRP has the ability to activate various immune
cells and has the capacity to bind to certain FcγRs. Both
CRP and IgG share a sequence homology that is import-
ant for FcγR binding [19]. The binding of CRP may
compete and interfere with the binding of protective
specific IgG antibodies. The R131 allele of FcγRIIa was
shown to bind CRP with high affinity [20]. CRP can in-
directly mediate activation of the complement and com-
plement receptors, or directly through receptors for the
FcγRs or even a putative CRP-specific receptor activa-
tion of immune cells.
The primary aim of this study is to examine the asso-
ciation between CRP gene polymorphism and serum
levels of CRP in correlation with early onset sepsis
(EOS) infection in newborns. The second aim of is to
examine the relationship between specific IgG/IgG sub-
classes and early onset sepsis (EOS) infection among
newborns living in Saudi Arabia.Methods
Study area
This study was conducted in Taif city in the western king-
dom of Saudi Arabia (KSA), at the Neonatal Intensive
Care unit (NICU), King Abdel Aziz Specialist Hospital
(KAASH), between March and August 2012. The KAASH
is one of the largest specialized hospitals in Taif city, with
a well-organized antenatal, postnatal clinics and NICU.Study design and patient enrolment
A prospective cohort (cross-sectional) study was carried
out over six months, between March and August 2012 in
NICU at KAASH-Taif. All neonates chosen for this study
were 40 ± 2 week gestation. This was specifically chosen to
minimise the differences in the IgG concentration ranges.
Gram negative organisms are the predominant patho-
gens associated with EOS. However, according to hos-
pital data from previous years, Staphylococcus aureus
was the commonest pathogen at KAASH hospital. As
such, we concentrated our efforts to investigate this par-
ticular pathogen [21].
The subjects were classified into three different
groups. Group I is the control group where babies have
no symptoms or signs of sepsis and a negative blood cul-
ture. Group II is the suspected group of neonates which
includes any infant with signs or symptoms of sepsis,
chorioamnionitis and those born to mothers who had
intrapartum temperature ≥38.0°C or prolonged rupture
of membrane ≥18 hours. It is important to note that
blood cultures for this group were negative. Once infec-
tion was confirmed by means of a positive blood culture
or blood markers, the infant was put into Group III
which is the early onset sepsis group.
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positive culture, were treated by clinicians (neonatologist)
with double antibiotics (Ampicilin [22] and Gentamicin
[23]) until the baby became symptom free or finished their
course of antibiotic. Once babies were examined clinically
and sepsis was confirmed; blood samples were taken
within 12-50 hours of birth as per our research protocol.
If the suspected neonate had an initial negative culture
but still continued to have symptoms/signs of sepsis; re-
peat cultures were offered within 72 hours. These neo-
nates were automatically excluded from the study. As
such, there were no repeat cultures taken.
Babies were clinically examined during their stay in
NICU. Full blood count was routinely taken. All investi-
gations and treatments were provided free of charge.
Neonates who were suspected of sepsis infection were
enrolled onto the study after ethical clearance was
obtained from the parents. Once the informed consent
was gained, peripheral blood samples were taken. Blood
samples were prepared for culture detection of bacterial
species and blood from each source was plotted in filter
paper. Newborns were weighed and those with low birth
weight were assessed clinically to differentiate between
intrauterine growth restriction or low birth weight using
Dubowitiz scoring system. This scoring system assesses
an infant for the apparent gestational age by considering
both neurologic and external signs of development.Sample collection
Before pharmacological treatment was started, 50 μl of
blood were collected on filter paper (Schleicher & Schuell;
n° 903TM) for DNA amplification, CRP detection and
measurement of immunoglobulin. Two ml of venous
blood sample was collected in EDTA VacutainerW tubes
(Becton Dickinson, Meylan, France) for microbiology
(bacterial) culture.DNA preparation
DNA was extracted from filter paper using a modified
version of the Chelex-100 method and stored at -20°C
[24,25]. In brief, 50 μl of peripheral blood was put on
the filter paper and incubated overnight in 1 ml of 0.5%
Saponin in PBS at 4°C. It was then washed for 15-30 mi-
nutes in 1 ml PBS at 4°C. The discs or the pellets were
boiled in 200 μl of 5% Chelex-100 in water for 15 mi-
nutes, and the DNA was collected in supernatants after
centrifugation at 10,000 rpm for 3 minutes.CRP genotyping with pyrosequencing
The CRP gene (tri-allelic SNP at position −286, C > T >
A) (rs3091244) was genotyped by pyrosequencing as
mentioned in the references opposite [26-28].Measurement of CRP
The serum concentrations of CRP were measured using
the same version of NycoCardW CRP Single Test (Axis-
Shield, Oslo, Norway), as described before by Israelsson
et al., [28].
Measurement of specific IgG and IgG subclasses by
enzyme-linked immunosorbent assays (ELISA)
An indirect enzyme-linked immunosorbent assay, ELISA
[29] was used for the measurement of total IgG and the
subclasses; IgG1, IgG2, IgG3 and IgG4, against specific
bacterial antigens of S. aureus, as described earlier [30]. In
brief, the plates were incubated overnight at 4°C, and then
blocked for 2 hours with 0.5% bovine serum albumin
(BSA) diluted in carbonate buffer (pH 9.6). Plasma sam-
ples diluted in incubation buffer (PBS + 0.5% BSA), 1:1000
(IgG) and 1:400 (IgG1-4), was added in duplicate and in-
cubated for 1 hour at 37°C. The plates were washed four
times, and bound IgG antibodies were detected with goat
anti-human IgG-ALP (1:2000) (Mabtech, Nacka, Sweden).
IgG subclasses were analyzed with their respective biotin
conjugated mouse anti-human subclass specific monoclo-
nal antibodies: mouse anti-human IgG1 1:1000 (M15015,
Clone NL16, SkyBio, Bedfordshire, UK), mouse anti-
human IgG2 1:3000 (555874, Pharmingen, Erembodegem,
Belgium), mouse anti-human IgG3 1:1000 (MH 1532,
Caltag laboratories, Paisley, UK) and mouse anti-human
IgG4 1:2000 (B3648, Sigma, St. Louis, USA). Alkaline
phosphatase (ALP) conjugated streptavidin (Mabtech) di-
luted 1:2000 was added to detect bound antibodies of
IgG2-4, while ALP-conjugated to goat anti-mouse Ig
(Dakopatts, Glostrup, Denmark; 1:1000) was used for
IgG1 antibodies and the plates were developed with
nitrophenyl phosphate (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany). The absorbance was read at 405 nm
using a Vmax™ Kinetic microplate reader (Molecular de-
vices, Menlo Park, USA).
Ethical considerations
This study has received ethical clearance from the Ethical
Committee of the College of Medicine, Taif University,
KSA. Informed consent was obtained from the neonates’
parents, who were going to participate in the study after
providing them with adequate information on the objec-
tives and benefits of the project.
Statistical analysis
Statistical analysis was performed by SPSS version 10.0
software for Windows (SPSSW, Inc, Chicago, IL, USA). In
this study, antibody levels (IgG and IgG subclass) were
analyzsed using Kruskal-Wallis test (non parametric) and
the P values were derived. With regards to the risk of
EOS, P values were considered significant if < 0.05. Over-
all, the 95% confidence interval (CI) for odds ratio (OR)
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explanation below).
 OR = 1 Represents no statistical significance
 OR > 1 Represents significance associated with the
EOS group
 OR < 1 Represents significance associated with the
suspected or sepsis free control
To assess the association between the CRP genotype
and sepsis outcomes (dependent variable), logistic re-
gression analysis was preformed. The CRP-TT genotype
was used as a reference value in the analyses.
Results
Characteristics of the study participants
A total of 205 newborns, were consecutively enrolled in
this study. The neonates were divided into three groups
according to presence of risk factors of early onset sepsis
(EOS); described previously in [31,32]. Group I; has 68 in-
fants with no evidences of sepsis infection (37 girls,
31 boys; median of age at time of collection was 1 day with
a range 1-2 days). Group II; has 68 infants suspected of
sepsis infection (25 girls, 43 boys; median of age at time of
collection was 1 day with a range of 1-2 days). Infants in
this group were symptomatic with or without maternal
risk factors and negative cultures, or asymptomatic with
maternal risk factors and negative blood culture. Group
III; has 69 infants with evidences of EOS infectionTable 1 Description of the study groups, sex, nationality, med
subclasses)
Study groups variables Sepsis- free controls n = 68
Sex: girls n(%) 37 (54.4%)
Boys n(%) 31 (45.6%)
Nationality: non-Saudi n(%) 8 (11.8%)
Saudi n(%) 60 (88.2%)
Median (range) of:
Age/ day 1 (1-2)
Weight/g 3390 (3095–4960)
Temperature/°C 36.7 (35.5–37.0)






TWBCs/ 103 cells/μl 10.43 (6.9–12.5)
Neutrophils% 3.24 (0.4–5.2)
Lymphocytes% 3.27 (0.78– 4.0)
Monocytes% 0.49 (0.09–0.71)(26 girls, 43 boys; median of age at time of collection was
1 day with a range of 1-1 day). Infants enrolled in this
group were symptomatic with or without maternal risk
factors and positive blood culture.
Newborns with sepsis infection were followed after
birth through the hospital neonatal unit and when pre-
senting with complaints.
The median (range) for the three study groups differed
statistically significantly in various clinical/laboratory pa-
rameters. Neonates diagnosed with EOS showed lower
weight/gm compared to suspected newborn and sepsis-
free controls [Overall P value < 0.001] (Table 1). The EOS
group had lower temperature °C compared to suspected
groups and sepsis-free controls [Overall P value < 0.001]
(Table 1). Furthermore, EOS patients showed higher levels
of CRP (ng/ml), total white blood cells count (TWBCs/
103 cells/μl), neutrophils (%), lymphocytes (%) and mono-
cytes (%) compared with sepsis-free controls and the
suspected group [Overall P value < 0.001 for each variable
previously mentioned] (Table 1).
The median (range) of specific IgG/IgG subclass anti-
bodies was statistically different between the study
groups (Table 1). Kruskal-Wallis (nonparametric) test
showed that the specific IgG/IgG subclass antibodies
were significantly higher in the suspected group com-
pared to sepsis-free controls and EOS [Overall P value <
0.001 and P value for IgG4 = 0.001] (Table 1). The most
dominant subclass amongst the specific antibodies was
IgG2 followed by IgG3, IgG1 and IgG4 in the suspectedian (range) for (weight, temperature, CRP, IgG and IgG
Suspected n = 68 Early onset sepsis n = 69 P value
25 (36.8%) 26 (37.7%) 0.06
43 (63.2%) 43 (62.3%)
4 (5.9%) 7 (10.1%) 0.48
64 (94.1%) 62 (89.9%)
1 (1-2) 1 (1-1) <0.091
2780 (2375–3175) 2030 (1335–2021) <0.001
35.3 (34.6–35.9) 35.5 (35.0–37.5) <0.001
3.46 (2.15–4.71) 6.43 (3.77–8.25) <0.001
2.05 (0.25–17.90) 0.57 (0.24–7.90) <0.001
5.60 (0.28–22.27) 3.20 (0.36–10.22) <0.001
8.37 (0.22–25.89) 1.52 (1.02–2.81) <0.001
6.50 (0.31–39.45) 4.78 (0.15–27.58) <0.001
0.34 (0.10–3.24) 0.39 (0.08–2.28) 0.001
14.45 (12.5–17.1) 21.72 (17.1–19.3) <0.001
7.17 (5.2–9.1) 12.25 (9.3–12.5) <0.001
4.79 (4.02–5.45) 6.76 (5.49–10.00) <0.001
1.51 (1.18–3.10) 1.5 (1.18–3.10) <0.001
Table 3 Logistic regression analysis of CRP -286 (C >T> A)
genotype polymorphism in early onset sepsis compared
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in EOS and sepsis free control groups.with suspected patients
CRP genotypes OR (95% CI) P value
TT 1.00
AA 0. 10 (0.01–1.27) <0.001
AC 0.05 (0.01–0.27) <0.001
AT 0.18 (0.03–1.07) 0.059
CC 7.88 (2.66–13.29) <0.001
CT 8.00 (2.46–16.04) 0.001
Alleles frequency
C 2.48 (0.97–6.37) 0.059
T 1.00
A 0.24 (0.10–0.57) 0.001
Alleles carriers frequency
Non-A-allele 0.13 (0.06–0.27) <0.001
A-alleleCRP genotypes, allele and allele carrier frequencies
All subjects within the three study groups were geno-
typed for − 286 C>T>A CRP single nucleotide poly-
morphism (SNP) in the CRP gene (rs3091244). Both
allele and genotype frequencies were found to be in
Hardy-Weinberg equilibrium (P value = 0.201) (Table 2).
The overall genotypic frequencies differed statistically sig-
nificantly between EOS patients compared to the suspected
group [OR = 1.34; 95% CI = (1.07- 1.67), P value = 0.010]
(Table 2). Logistic regression analyses showed that the
AA and AC genotypes were negatively associated
amongst EOS patients compared to suspected neonates
when using the TT genotype as a reference group in the
analysis [1.4% for EOS versus 22.1% for suspected
group; OR 0.10; 95% CI (0.01-1.27) and P value < 0.001]
and [14.5% for EOS versus 44.1% for the suspected
group; OR 0.05; 95% CI (0.01-0.27) and P value < 0.001]
respectively (Tables 2 and 3). For AT genotype, there
were no statistical differences between EOS patients
compared to the suspected group [11.6% for EOS pa-
tients versus 10.3% for the suspected group; OR 0.18;
95% CI (0.03- 1.07) and P value = 0.059] (Tables 2 and 3).
The frequency of CC and CT were significantly associated
with the EOS patients compared to the suspected group
[30.4% for EOS versus 11.8% for the suspected group;
OR 7.88; 95% CI (2.66- 13.29) and P value < 0.001] and
[23.2% for EOS versus 8.8% for the suspected group; OR
8.00; 95% CI (2.46-16.04) and P value = 0.001] respect-
ively (Tables 2 and 3).Table 2 Description of CRP -286 (C>T>A) genotype polymorph
CRP genotypes* Sepsis- free controls n = 68 (%) Suspected n = 68 (%
TT 10 (14.7%) 2 (2.9%)
AA 3 (4.4%) 15 (22.1%)
AC 19 (27.9%) 30 (44.1%)
AT 13 (19.1%) 7 (10.3%)
CC 18 (26.5%) 8 (11.8%)






Non- A- Allele 33 (48.5%) 16 (23.5%)
A- Allele 35 (51.5%) 52 (76.5%)
* Overall genotypic frequency; Odds Ratio [OR] = 1.34; 95% Confidence Interval [CI]
‡ Overall allelic frequency; OR = 3.28; 95% CI = (1.92-5.59), P value < 0.001.
§ Overall allelic carriers; OR = 5.11; 95% CI = (1.74- 8.01), P value = 0.003.With regards to CRP allele frequencies; there were
significant differences between the study groups [Over-
all allelic frequency; OR = 3.28; 95% CI = (1.92-5.59),
P value < 0.001] (Tables 2). The A allele being less fre-
quent than the C allele amongst EOS patients [0.14%
for EOS versus 0.49% for suspected groups; OR = 3.28;
95% CI = (1.92-5.59), P value < 0.001] (Tables 2 and 3).
As per Kovacs et al., 2005, findings, we adopted the
same method of comparing individuals carrying the A al-
lele against those who are non-A allele carriers [14]. The
frequency of the A-allele carriers was dominant in new-
borns with sepsis infections compared to the suspected
group [29% for EOS patients versus 76.5% for suspectedism in the study groups












= (1.07- 1.67), P value = 0.010.
Table 5 Logistic regression analysis of CRP levels (ng/ml)
in relation to CRP-286 A-allele compared with non-A-
allele carriers in the combined study population
CRP levels ng/ml OR (95% CI) p value
Less than 0.239 0.38 (0.18–0.77) 0.007
Within 0.240 to 1.300 1.00
Higher than 1.301 3.24 (1.53–6.87) 0.002
OR represent odds ratios while CI represents confidence intervals. Non-A-allele
carriers were assigned 0; A-allele carriers were assigned 1 in the logistic
regression analysis. OR above 1 represented value associated to A-allele
carriers while less than 1 value represented non-A-allele carriers.
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(Tables 2 and 3).
Circulating CRP concentrations
In this study, serum CRP concentration levels were
analysed in the study groups to quantify the independent
relationship between the risk of sepsis infection and
CRP levels. The CRP levels were grouped into third of
their distributions and comparisons were made with the
second categorised level as a reference value.
Logistic regression analysis revealed that levels of
CRP were significantly higher amongst EOS compared
to the suspected group [OR = 2.31; 95% CI = (1.16-4.59),
P value = 0.005] (Table 4).
Analysis of CRP concentrations in relation to CRP-286
allele carriers
The distribution of CRP-286 allele carriers and CRP levels
in the whole study groups were analysed. Logistic regres-
sion analysis test showed that higher levels of CRP were as-
sociated with A-allele carriers than those with non-A-allele
carriers [OR = 3.24; 95% CI = (1.53-6.87), P value = 0.002]
(Table 5). The lower level of CRP was associated with non-
A-allele carriers of CRP-286 were seen in the study po-
pulation [OR = 0.38; 95% CI = (0.18-0.77), P value = 0.007]
(Table 5).
Patterns of specific IgG/IgG subclass antibodies in relation
to relative risk of sepsis infection
Newborns with early onset sepsis infection were used as a
dependent variable in the statistical analyses. The levels of
anti-S. aureus antibodies of IgG/IgG subclasses were sta-
tistically different between the EOS and suspected groups.
To quantify the independent relationship between the
relative risk of sepsis infection and IgG antibody titer; the
antibody levels were ranked into three groups according
to their distribution. Comparisons were made with the
lowest concentration (first group), which was used as a
reference value. Although there were higher levels of anti-
S. aureus IgG1, IgG2 and IgG3 antibodies in the suspected
group, they were independently associated with a reduced
risk of EOS infection [OR = 0.30; 95% CI = (0.12-0.76),
P value < 0.011], [For medium level of IgG2; OR = 0.44;
95% CI = (0.37-0.73), P value = 0.001 and for higher level
of IgG2 OR = 0.34; 95% CI = (0.20-0.49), P value = 0.030]Table 4 Logistic regression analysis of CRP levels (ng/ml)
in relation to the risk of early onset sepsis compared
with suspected patients
CRP levels ng/ml OR (95% CI) p value
Less than 0.239 0.52 (0.22–1.21) 0.129
Within 0.240 to 1.300 1.00
Higher than 1.301 2.31 (1.16–4.59) 0.005and [OR = 0.32; 95% CI = (0.13-0.75), P value = 0.009]
respectively (Table 6). For the IgG4 antibody was found
to be statistically higher in the EOS than the suspected
group [OR = 2.82; 95% CI = (1.16-6.90), P value = 0.023]
(Table 6).
Concentration of serum CRP levels in relation to relative
risk of high levels of specific IgG/IgG subclass antibodies
In order to see if the specific IgG/IgG subclass antibodies
levels have affected the concentration of CRP, the relation-
ship between IgG antibody subclasses and CRP were
analysed. In all of the study populations, the lower concen-
tration of IgG2 was associated with higher levels of serum
CRP level [OR = 0.74; 95% CI = [0.35-1.06], P value = 0.034]
(Table 7). No statistical differences in levels of IgG1, IgG3
and IgG4 were seen among the different CRP levels
(Table 7).
Discussion
In this study, the majority of infants (66.8%) were diag-
nosed with suspected or proven EOS and were admitted
to the NICU. All of the study population was evaluated
for sepsis during the first week of life. Only 33.7% of the
newborns had a confirmed episode of EOS. Currently,
there are management guidelines addressing the need
for sepsis evaluation in EOS.
It is possible that a large proportion of EOS remains
culture negative due to various reasons like low bacterial
load, low volumes of blood taken for culture, and mater-
nal antibiotic therapy.
This study looked at whether clinical signs such as
temperature were measured for the study population.
Interestingly, it was found that the EOS and suspected
groups had lower temperatures compared with sepsis-
free controls. To our knowledge, neonatal fever may
occur when secretion of pyretic inflammatory cytokines
raises the hypothalamic temperature set point, leading to
heat-conservation and heat-generation by physiologic re-
sponses. However, mechanisms besides inflammatory pat-
terns may also lead to an elevated body temperature
[33-36]. Non-infectious conditions associated with neo-
natal fever include dehydration, breast-feeding, high birth
Table 6 Logistic regression analysis of IgG subclasses in relation to the risk of early onset sepsis compared with
suspected patients
Antibody isotopes Categorized IgG subclasses levels OR (95% CI) P value
IgG Lower level 1.00
Medium level 0.69 (0.29–1.62) 0.394
Higher level 0.213 (0.09–0.51) <0.001
IgG1 Lower level 1.00
Medium level 1.34 (0.51–3.50) 0.558
Higher level 0.30 (0.12–0.76) 0.011
IgG2 Lower level 1.00
Medium level 0.44 (0.37– 0.73) 0.001
Higher level 0.34 (0.20–0.49) 0.030
IgG3 Lower level 1.00
Medium level 0.44 (0.18–1.07) 0.070
Higher level 0.32 (0.13–0.75) 0.009
IgG4 Lower level 1.00
Medium level 2.82 (1.16–6.90) 0.023
Higher level 1.71 (0.73–4.00) 0.213
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may also elevate the newborn’s temperature [40,41]. Over-
all rates of temperatures in EOS infants were very low,
making this sign a highly specific diagnostic tool in the
diagnosis of bacterial infection. The vast majority of in-
fants presenting with high temperatures suffered severe ill-
nesses and/or had other organ systems involved. HighTable 7 Logistic regression analysis of CRP levels in ng/ml in
study populations
Antibody isotopes Categorized CRP levels
IgG Less than 0.239
Within 0.240 to 1.300
Higher than 1.301
IgG1 Less than 0.239
Within 0.240 to 1.300
Higher than 1.301
IgG2 Less than 0.239
Within 0.240 to 1.300
Higher than 1.301
IgG3 Less than 0.239
Within 0.240 to 1.300
Higher than 1.301
IgG4 Less than 0.239
Within 0.240 to 1.300
Higher than 1.301
To quantify the independent relationship between antibodies isotype (were ranked
grouped into third of their distributions and comparisons were made with last cate
ratios while CI represents confidence intervals. Lower concentration of antibodies w
logistic regression analysis. OR above 1 represented value associated to higher con
concentration of antibodies.temperatures were extremely rare in an otherwise healthy
infant without any other signs of illness.
Our results suggest that babies with EOS had a signifi-
cantly lower median weight (2030 g) compared to
suspected (2780 g)/or sepsis-free controls (3390 g).
This study demonstrates an association between CRP-
286 (A allele) and EOS whereby carriers of the A allele arerelation to higher antibodies isotype in the combined
















into two groups of their distributions), and CRP levels. The CRP levels were
gorized level (higher concentration) as reference value. OR represent odds
as assigned 0; higher concentration of antibodies was assigned 1 in the
centration of antibodies while less than 1 value represented lower
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group. High levels of CRP were associated with EOS com-
pared with the suspected group. Furthermore, EOS was
associated with high levels of total white blood cells
(TWBC), neutrophils and lymphocytes. This finding is in
agreement with previous reports by Berger et al., 1995
which showed that high levels of CRP, TWBC and lym-
phocytes were comparably good tests during the first three
days of life, and that CRP was the best test in the early de-
tection of neonatal septicaemia [42].
A previous study showed that CRP secretion starts
within 4–6 hours after stimulation, peaking only after
36 hours [43]. Early reports described a high prevalence of
elevated CRP levels in infected infants, but levels are ele-
vated in only 35% to 65% of neonates with bacterial infec-
tion at the onset of illness [44]. Recognition that a delay of
at least several hours is intrinsic to the cascade of events
leading to elevation of serum CRP levels (including activa-
tion of neutrophils, elaboration of interleukin-6 (IL-6),
and induction of hepatic synthesis of CRP) [45] led to ap-
propriate criticism of this test as having insufficient sensi-
tivity to guide therapy either by reliably diagnosing or
excluding bacterial infection [45].
The results obtained in this study (combined study
group) have shown higher levels of CRP associated with
A-allele carriers (high producer allele) of the CRP-286
(C>T>A) in symptomatic group compared to sepsis free
controls. This result mirrors a previous study which
found a similar relationship between higher frequencies
of A-allele carriers and higher concentration of serum
CRP levels [14]. Our data is in agreement with a recent
study which focused on deep infections, where CRP-286
(C>T>A) polymorphism is found to be significantly as-
sociated with maximal CRP levels during the first week
of infection [46]. Interestingly, this same triallelic CRP-
286 (C>T>A) polymorphism, which we found to be as-
sociated with maximal CRP levels in S. aureus bacter-
aemia, has been related to high basal CRP levels as well
[14,46-49]. The triallelic SNP association with CRP level
strongly supports recent work described above and rep-
resents a reproducible association between genetic vari-
ation and this biomarker of high interest. It is known
that CRP does not cross the placenta [50]. It is therefore
possible to, all the measured levels of CRP are produced
by the neonates themselves. Accordingly, previous studies
confirm that serum concentrations of CRP and its produc-
tion in the mother, fetus/newborn are independent of one
another; however, the same stimulus may be operating
concurrently in each [51]. The major obstetric condition
in which determination of maternal serum CRP concen-
trations might be clinically useful is chorioamnionitis [52].
In this study, we investigated IgG/IgG subclasses as one
of the factors of complement activation. The current data
showed that the specific antibody levels of IgG, IgG1,IgG2, and IgG3 were statistically significantly higher in the
suspected neonates compared with the EOS group. Much
of the knowledge of effector functions of IgG subclasses
has been obtained from previous studies with aggregated
myeloma proteins, showing that IgG1 binds the comple-
ment effectively than IgG2 [53-55]. A recent study in
autoimmune disease suggests that the elevated levels of
immune complexes (ICs) are associated with increased
levels of IgG1 and decreased levels of C3 and C4 in cases
of autoimmune pancreatitis, since IgG1 is a molecule cap-
able of activation of the classical pathway [56]. A previous
study suggests that the high levels of specific IgG3 anti-
bodies are able to induce a high level of complement acti-
vation, and can probably induce local immune complex
formation [57]. Given this, it is probable that in our study,
the activation of complement via the classical pathway in
the sepsis patients might be caused by IGs including the
IgG subclasses except for IgG4. However, further studies
are needed to investigate the levels of C3 and C4 in pa-
tients with S. aureus infection.
This study demonstrates higher levels of specific IgG2
than IgG3 and IgG1 in suspected newborns compared to
EOS groups. The four human IgG subclasses are known
to differ in their ability to activate complement [58,59].
Specifically, IgG1 and IgG3 antibodies efficiently activate
the complement system, whereas IgG2 antibodies are ef-
fective mainly at high epitope density, and IgG4 anti-
bodies are ineffective complement activators [59,60].
In general, the high levels of IgG and IgG subclasses can
indicate that the mother of the neonate had a previous in-
fection with S. aureus during pregnancy. This may subse-
quently increase the levels of specific IgG antibodies in the
newborn, given that IgG is the only antibody that can
cross the placenta. Recent studies mentioned that the anti-
body transfer from mother to baby is an active process
that starts early around the gestational age of 16 weeks,
but an abundance of IgG is acquired later, during the last
4 weeks of full-term pregnancy [61,62]. The transporta-
tion of IgG is likely to depend on placental receptors for
the Fc part of the antibody (IgG Fc receptor [FcγR]).
FcγR I and III have a preference for IgG1 and IgG3 and
low affinity for IgG2 [63]. However, FcγRIIa has a high
affinity to bind IgG2 [64]. This has potential impact on
the transfer of antibodies directed to different antigens,
because polysaccharides are likely to elicit more IgG2
antibodies [65,66], whereas IgG1 and IgG3 subclasses
are directed primarily to proteins [67,68]. Factors such
as gestational age of the infant at birth, placental abnor-
malities, and the concentration of specific IgG sub-
classes in the mother also influence the concentrations
in the newborn [68,69]. In addition, the impact of differ-
ent types of FcγR polymorphism on IgG subclasses and
susceptibility to sepsis infection in the newborn is im-
portant to investigate.
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which is one of its main mechanisms in providing host de-
fence [70]. It has recently been recognised that CRP inter-
acts with the cells of the immune system by binding to
FcγRIIa [19,71]. It may thus bridge the gap between innate
and adaptive immunity and provide an early, effective anti-
bacterial response. Furthermore, as it protects against the
damaging inflammatory response to lipopolysaccharide
and cytokines, it may prevent the lethal side-effects of bac-
terial products [72]. The recent identification of the inter-
action of CRP with FcγR will lead to an enhanced
understanding of CRP and its role in both the innate and
acquired immune systems [19,71].
This study suggested that higher levels of CRP were
negatively associated with levels of IgG2. CRP and IgG
share a sequence homology that is important for FcγRIIa
binding [19]. The binding of CRP may compete and inter-
fere with the binding of protective specific IgG antibodies
[19]. This finding may explain the important role that high
levels of IgG2 can play in reducing the risk of EOS infec-
tion in the neonates. The observation in this study pro-
vides additional evidence that IgG2 is a good activator of
the classical complement pathway. When put together, it
is thought that CRP and IgG have several functions in-
cluding opsonisation [73-75], complement activation by
binding C1q [76,77], and binding to FcγR [78,79].Conclusions
Taken together, the CRP-286 (C>T>A) genotype poly-
morphism and specific IgG antibody subclass levels
against neonates infected with S. aureus, may contribute
to a reduced risk of EOS infection in neonates living in
Saudi Arabia. Furthermore, babies carrying the A-allele
were associated with high levels of circulating CRP. The
higher IgG2 antibody levels associated with lower levels of
circulating CRP seen in the study population may be due
to the competition between CRP and IgG2 to binding
FcγRIIa. Expectedly, the results of this study suggest that
the magnitude and the quality of anti-sepsis antibodies
(humoral response) are not the only key elements for rela-
tive reduction in sepsis infection outcomes. Rather, the re-
sults suggest that CRP acting non-specifically, may
contribute to the bacterial infection clearance. However,
further studies are needed to elucidate whether the
FcγRIIa-R/H131 polymorphism is a contributing factor to
the differential susceptibility to sepsis infection.Abbreviations
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